CHRS
Price
$1.50
Change
+$0.05 (+3.45%)
Updated
Sep 26 closing price
Capitalization
174.34M
44 days until earnings call
XENE
Price
$37.98
Change
+$1.46 (+4.00%)
Updated
Sep 26 closing price
Capitalization
2.93B
39 days until earnings call
Interact to see
Advertisement

CHRS vs XENE

Header iconCHRS vs XENE Comparison
Open Charts CHRS vs XENEBanner chart's image
Coherus Oncology
Price$1.50
Change+$0.05 (+3.45%)
Volume$1.57M
Capitalization174.34M
Xenon Pharmaceuticals
Price$37.98
Change+$1.46 (+4.00%)
Volume$680.07K
Capitalization2.93B
CHRS vs XENE Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. XENE commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a StrongBuy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (CHRS: $1.50 vs. XENE: $37.98)
Brand notoriety: CHRS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 110% vs. XENE: 82%
Market capitalization -- CHRS: $174.34M vs. XENE: $2.93B
CHRS [@Biotechnology] is valued at $174.34M. XENE’s [@Biotechnology] market capitalization is $2.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, CHRS is a better buy in the long-term than XENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, XENE is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -6.83% price change this week, while XENE (@Biotechnology) price change was +2.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.93B) has a higher market cap than CHRS($174M). CHRS YTD gains are higher at: 8.696 vs. XENE (-3.112). CHRS has higher annual earnings (EBITDA): 88.2M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. CHRS (238M). XENE has less debt than CHRS: XENE (8.72M) vs CHRS (41M). CHRS has higher revenues than XENE: CHRS (272M) vs XENE (7.5M).
CHRSXENECHRS / XENE
Capitalization174M2.93B6%
EBITDA88.2M-315.5M-28%
Gain YTD8.696-3.112-279%
P/E Ratio2.83N/A-
Revenue272M7.5M3,627%
Total Cash238M488M49%
Total Debt41M8.72M470%
FUNDAMENTALS RATINGS
CHRS vs XENE: Fundamental Ratings
CHRS
XENE
OUTLOOK RATING
1..100
8061
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
597
PRICE GROWTH RATING
1..100
3756
P/E GROWTH RATING
1..100
846
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for XENE (72). This means that CHRS’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (39) in the Biotechnology industry is somewhat better than the same rating for CHRS (100). This means that XENE’s stock grew somewhat faster than CHRS’s over the last 12 months.

CHRS's SMR Rating (5) in the Biotechnology industry is significantly better than the same rating for XENE (97). This means that CHRS’s stock grew significantly faster than XENE’s over the last 12 months.

CHRS's Price Growth Rating (37) in the Biotechnology industry is in the same range as XENE (56). This means that CHRS’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for CHRS (84). This means that XENE’s stock grew significantly faster than CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
61%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 10 days ago
73%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 3 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RAFA0.05N/A
+2.06%
Rafarma Pharmaceuticals, Inc. (WY)
CKHGY101.810.27
+0.27%
Capitec Bank Holdings Ltd
DCHIF0.38N/A
N/A
Digital China Holdings Ltd.
KOTMY15.30N/A
N/A
Koito Manufacturing Co., Ltd.
GGLDF0.31N/A
-1.47%
Getchell Gold Corporation

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+3.45%
XENE - CHRS
40%
Loosely correlated
+4.00%
XNCR - CHRS
37%
Loosely correlated
+12.00%
RXRX - CHRS
34%
Loosely correlated
+1.94%
DNA - CHRS
34%
Loosely correlated
+2.22%
SRRK - CHRS
33%
Loosely correlated
+12.35%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with NUVL. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+4.00%
NUVL - XENE
60%
Loosely correlated
+4.99%
IDYA - XENE
56%
Loosely correlated
+4.44%
CRNX - XENE
54%
Loosely correlated
+27.92%
IMVT - XENE
52%
Loosely correlated
+3.57%
NRIX - XENE
51%
Loosely correlated
+7.20%
More